{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:02:10Z","timestamp":1790283730775,"version":"4.1.0"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Guangxi Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.intimp.2026.117461","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:20:29Z","timestamp":1790209229000},"page":"117461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CAR-based therapies in systemic autoimmunity: from deep immune depletion toward durable immune reset"],"prefix":"10.1016","volume":"189","author":[{"given":"Hongyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baixiu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengquan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaile","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.117461_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.681062","article-title":"Strategies to use nanoparticles to generate CD4 and CD8 regulatory T cells for the treatment of SLE and other autoimmune diseases","volume":"12","author":"Horwitz","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117461_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.814857","article-title":"The role of B1 cells in systemic lupus erythematosus","volume":"13","author":"She","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117461_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.654701","article-title":"Potential for antigen-specific tolerizing immunotherapy in systematic lupus erythematosus","volume":"12","author":"Robinson","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117461_bb0020","doi-asserted-by":"crossref","DOI":"10.2196\/44660","article-title":"Listening to patients with lupus: why not proactively integrate the internet as a resource to drive improved care?","volume":"25","author":"Blackie","year":"2023","journal-title":"J. Med. Internet Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2026.117461_bb0030","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-med-060622-100940","article-title":"New therapeutic approaches to large-vessel Vasculitis","volume":"75","author":"Kaymakci","year":"2024","journal-title":"Annu. Rev. Med."},{"issue":"5","key":"10.1016\/j.intimp.2026.117461_bb0035","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/joim.70017","article-title":"Predictors of remission and relapse in retroperitoneal fibrosis","volume":"298","author":"Bond","year":"2025","journal-title":"J. Intern. Med."},{"issue":"6","key":"10.1016\/j.intimp.2026.117461_bb0040","doi-asserted-by":"crossref","first-page":"531","DOI":"10.7555\/JBR.38.20240009","article-title":"Systemic lupus erythematosus therapeutic strategy: from immunotherapy to gut microbiota modulation","volume":"38","author":"Chasov","year":"2024","journal-title":"J. Biomed. Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00281-024-01034-5","article-title":"Current advancements in cellular immunotherapy for autoimmune disease","volume":"47","author":"Berry","year":"2025","journal-title":"Semin. Immunopathol."},{"issue":"18","key":"10.1016\/j.intimp.2026.117461_bb0050","doi-asserted-by":"crossref","first-page":"9944","DOI":"10.7150\/thno.121766","article-title":"GM-CSF(+) Th: a central player in autoimmunity","volume":"15","author":"Fan","year":"2025","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.intimp.2026.117461_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70101","article-title":"The emerging role of neutrophil extracellular traps in autoimmune and autoinflammatory diseases","volume":"6","author":"Zeng","year":"2025","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0060","doi-asserted-by":"crossref","DOI":"10.1111\/imr.70047","article-title":"Perivascular tertiary lymphoid structures in autoimmune disease","volume":"332","author":"Goronzy","year":"2025","journal-title":"Immunol. Rev."},{"issue":"67","key":"10.1016\/j.intimp.2026.117461_bb0065","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abf5314","article-title":"Lung-resident memory B cells established after pulmonary influenza infection display distinct transcriptional and phenotypic profiles","volume":"7","author":"Tan","year":"2022","journal-title":"Sci. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0070","doi-asserted-by":"crossref","DOI":"10.1111\/imr.70088","article-title":"T peripheral helper cells in lymphoid aggregate and tertiary lymphoid structure formation","volume":"337","author":"Sowerby","year":"2026","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-42625-4","article-title":"Tissue-resident B cells orchestrate macrophage polarisation and function","volume":"14","author":"Suchanek","year":"2023","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.intimp.2026.117461_bb0080","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/s42255-025-01331-9","article-title":"Lactate signalling leads to aggregation of immune-inflammatory hotspots and SLC5A12 blockade promotes their resolution","volume":"7","author":"Certo","year":"2025","journal-title":"Nat. Metab."},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-immunol-083122-044829","article-title":"B cell-directed therapy in autoimmunity","volume":"42","author":"Abeles","year":"2024","journal-title":"Annu. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117461_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103859","article-title":"Chimeric antigen receptor cell therapy: a revolutionary approach transforming cancer treatment to autoimmune disease therapy","volume":"24","author":"Wen","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2026.117461_bb0095","doi-asserted-by":"crossref","first-page":"1581323","DOI":"10.3389\/fimmu.2025.1581323","article-title":"Emerging B and plasma cell-targeting immune therapies in idiopathic inflammatory myopathies","volume":"16","author":"Groener","year":"2025","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117461_bb0100","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"issue":"18","key":"10.1016\/j.intimp.2026.117461_bb0105","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1016\/j.cell.2024.07.056","article-title":"Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases","volume":"187","author":"Baker","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12016-025-09113-7","article-title":"CAR T cell therapy for rheumatoid arthritis","volume":"68","author":"Freeley","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.intimp.2026.117461_bb0115","article-title":"Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: a case study","volume":"204","author":"Subklewe","year":"2024","journal-title":"European journal of cancer (Oxford, England\u202f: 1990)"},{"key":"10.1016\/j.intimp.2026.117461_bb0120","first-page":"0712","article-title":"Revolutionizing autoimmune kidney disease treatment with chimeric antigen receptor-T cell therapy","volume":"8","author":"Gu","year":"2025","journal-title":"Research (Washington, DC)"},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0125","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-026-08262-3","article-title":"A new hope with CAR T-cell therapy for refractory idiopathic inflammatory myopathies: a systematic review","volume":"24","author":"Shan","year":"2026","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117461_bb0130","doi-asserted-by":"crossref","first-page":"1465191","DOI":"10.3389\/fimmu.2024.1465191","article-title":"Application of novel CAR technologies to improve treatment of autoimmune disease","volume":"15","author":"Cheever","year":"2024","journal-title":"Front. Immunol."},{"issue":"835","key":"10.1016\/j.intimp.2026.117461_bb0135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adr9382","article-title":"Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells","volume":"18","author":"Cohen","year":"2026","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117461_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.101002","article-title":"Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: other modes of transportation","volume":"57","author":"Sermer","year":"2023","journal-title":"Blood Rev."},{"issue":"2","key":"10.1016\/j.intimp.2026.117461_bb0145","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200080","article-title":"CAR-T cell-mediated B-cell depletion in central nervous system autoimmunity","volume":"10","author":"Gupta","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"11","key":"10.1016\/j.intimp.2026.117461_bb0150","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1182\/bloodadvances.2022008697","article-title":"A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy","volume":"7","author":"Hirayama","year":"2023","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.intimp.2026.117461_bb0155","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1158\/2326-6066.CIR-21-0626","article-title":"Regulatory programs of B-cell activation and germinal Center reaction allow B-ALL escape from CD19 CAR T-cell therapy","volume":"10","author":"Im","year":"2022","journal-title":"Cancer Immunol. Res."},{"issue":"10416","key":"10.1016\/j.intimp.2026.117461_bb0160","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet (London, England)"},{"issue":"24","key":"10.1016\/j.intimp.2026.117461_bb0165","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with Antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.intimp.2026.117461_bb0170","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/bjh.20061","article-title":"CD19 chimeric antigen receptor-T cell therapy in murine immune thrombocytopenia","volume":"206","author":"Han","year":"2025","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0175","article-title":"Promising effects of CAR T-cell therapy in refractory stiff person syndrome and a hopeful future for all Neuroautoimmunities","volume":"13","author":"Dalakas","year":"2026","journal-title":"Neurology(R) neuroimmunology & neuroinflammation"},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0180","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-026-01779-6","article-title":"BCMA-CD19 armored compound CAR T cells in systemic lupus erythematosus: extended follow-up of a phase 1 clinical trial","volume":"19","author":"Hong","year":"2026","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.117461_bb0185","doi-asserted-by":"crossref","first-page":"1731285","DOI":"10.3389\/fimmu.2025.1731285","article-title":"Aberrant B cell responses as drivers of autoantibody generation and epitope diversification in SLE pathogenesis","volume":"16","author":"Tariq","year":"2025","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2026.117461_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103687","article-title":"Harnessing the potential of CAR-T cell in lupus treatment: from theory to practice","volume":"23","author":"Alsuliman","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2026.117461_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.970906","article-title":"IL-10 revisited in systemic lupus erythematosus","volume":"13","author":"Biswas","year":"2022","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117461_bb0200","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/art.42157","article-title":"Plasmablast-like phenotype among antigen-experienced CXCR5-CD19(low) B cells in systemic lupus erythematosus","volume":"74","author":"Szelinski","year":"2022","journal-title":"Arthritis & rheumatology (Hoboken, N.J.)"},{"issue":"10","key":"10.1016\/j.intimp.2026.117461_bb0205","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011768","article-title":"Acquisition of an immunosuppressive microenvironment after anti-CD19 CAR T-cell therapy is associated with T-cell dysfunction and resistance","volume":"13","author":"Ponzo","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.117461_bb0210","article-title":"B-cell maturation antigen-CD19 dual-targeted chimeric antigen receptor- T-cell therapy for relapsed or refractory AL amyloidosis","author":"Huang","year":"2026","journal-title":"Journal of the American Society of Nephrology\u202f: JASN"},{"issue":"11","key":"10.1016\/j.intimp.2026.117461_bb0215","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","article-title":"Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Feng","year":"2025","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.intimp.2026.117461_bb0220","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood cancer discovery"},{"issue":"6","key":"10.1016\/j.intimp.2026.117461_bb0225","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1158\/2643-3230.BCD-23-0157","article-title":"Understanding infection risk with anti-BCMA bispecific antibodies","volume":"4","author":"Garfall","year":"2023","journal-title":"Blood cancer discovery"},{"key":"10.1016\/j.intimp.2026.117461_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1539773","article-title":"Decoding plasma cell maturation dynamics with BCMA","volume":"16","author":"Schulz","year":"2025","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117461_bb0235","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01114-2024","article-title":"Distinct mural cells and fibroblasts promote pathogenic plasma cell accumulation in idiopathic pulmonary fibrosis","volume":"65","author":"Yang","year":"2025","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2026.117461_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103495","article-title":"Chimeric antigen receptor T cell therapy: a new frontier therapeutic landscape in autoimmune diseases","volume":"157","author":"An","year":"2025","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.intimp.2026.117461_bb0245","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/bjh.18747","article-title":"Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy","volume":"202","author":"Kitamura","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0250","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41421-025-00861-6","article-title":"Integrating single-nucleus barcoding with spatial transcriptomics via stamp-seq to reveal immunotherapy response-enhancing functional modules in NSCLC","volume":"12","author":"Pan","year":"2026","journal-title":"Cell Discov."},{"issue":"6","key":"10.1016\/j.intimp.2026.117461_bb0255","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"Muller","year":"2025","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.intimp.2026.117461_bb0260","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.intimp.2026.117461_bb0265","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/path.6353","article-title":"APRIL\/BAFF upregulation is associated with clonal B-cell expansion in Hunner-type interstitial cystitis","volume":"264","author":"Horie","year":"2024","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0270","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/s41467-025-68264-5","article-title":"Altered B cell activation contributes to the immunopathogenesis of childhood arthritis-associated uveitis","volume":"17","author":"Jebson","year":"2026","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.intimp.2026.117461_bb0275","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41590-022-01230-1","article-title":"Clonal structure, stability and dynamics of human memory B cells and circulating plasmablasts","volume":"23","author":"Phad","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2026.117461_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1123968","article-title":"Exploring the impact of clonal definition on B-cell diversity: implications for the analysis of immune repertoires","volume":"14","author":"Pelissier","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0285","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70062","article-title":"Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed\/refractory B-cell lymphoma","volume":"9","author":"Stock","year":"2025","journal-title":"HemaSphere"},{"issue":"9","key":"10.1016\/j.intimp.2026.117461_bb0290","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood.2025028375","article-title":"Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma","volume":"146","author":"Muller","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2026.117461_bb0295","first-page":"487","article-title":"The endogenous repertoire harbors self-reactive CD4(+) T cell clones that adopt a follicular helper T cell-like phenotype at steady state","volume":"24","author":"Lee","year":"2023","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0300","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0305","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1038\/s41467-024-46654-5","article-title":"Targeting pathogenic CD8(+) tissue-resident T cells with chimeric antigen receptor therapy in murine autoimmune cholangitis","volume":"15","author":"Zhu","year":"2024","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.intimp.2026.117461_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103185","article-title":"T cell abnormalities in systemic sclerosis","volume":"21","author":"Jin","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2026.117461_bb0315","doi-asserted-by":"crossref","unstructured":"Kirou RA, Pinal-Fernandez I, Casal-Dominguez M, Pak K, Ikenaga C, Nelke C, Wischnewski S, Preusse C, Del Orso S, Naz F et al: Myeloid dendritic cell subsets characterise muscle in patients with inclusion body myositis and correlate with the IFN-gamma pathway and effector T cell markers. Ann. Rheum. Dis. 2026.","DOI":"10.1016\/j.ard.2026.03.001"},{"issue":"18","key":"10.1016\/j.intimp.2026.117461_bb0320","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1111\/bph.15512","article-title":"Gut microbiota contributes to the development of hypertension in a genetic mouse model of systemic lupus erythematosus","volume":"178","author":"de la Visitacion","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0325","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1038\/s41467-025-60034-7","article-title":"Single-cell analysis reveals immune cell abnormalities underlying the clinical heterogeneity of patients with systemic sclerosis","volume":"16","author":"Shimagami","year":"2025","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.intimp.2026.117461_bb0330","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"The Lancet Rheumatology"},{"issue":"4","key":"10.1016\/j.intimp.2026.117461_bb0350","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41573-025-01349-4","article-title":"Roads and detours for CAR T cell therapy in autoimmune diseases","volume":"25","author":"Avouac","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.intimp.2026.117461_bb0355","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70658","article-title":"Application and challenges of chimeric antigen receptor T cell therapy in systemic rheumatic diseases and autoimmune disorders","volume":"7","author":"Fan","year":"2026","journal-title":"MedComm"},{"issue":"3","key":"10.1016\/j.intimp.2026.117461_bb0360","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/S2665-9913(24)00240-6","article-title":"Barriers to CAR T-cell therapy in rheumatology","volume":"7","author":"Lungova","year":"2025","journal-title":"The Lancet Rheumatology"},{"issue":"7","key":"10.1016\/j.intimp.2026.117461_bb0365","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41577-025-01141-w","article-title":"Defining immune reset: achieving sustained remission in autoimmune diseases","volume":"25","author":"Junt","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2026.117461_bb0370","doi-asserted-by":"crossref","first-page":"1604174","DOI":"10.3389\/fimmu.2025.1604174","article-title":"CAR T-cells meet autoimmune neurological diseases: a new dawn for therapy","volume":"16","author":"Chinas","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117461_bb0375","doi-asserted-by":"crossref","unstructured":"Avouac J, Cauvet A, Orvain C, Boulch M, Tilotta F, Tu L, Thuillet R, Ottaviani M, Guignabert C, Bousso P et al: Effects of B cell depletion by CD19-targeted chimeric antigen receptor T cells in a murine model of systemic sclerosis. Arthritis & rheumatology (Hoboken, NJ) 2024, 76(2):268\u2013278.","DOI":"10.1002\/art.42677"},{"key":"10.1016\/j.intimp.2026.117461_bb0380","doi-asserted-by":"crossref","first-page":"1101446","DOI":"10.3389\/fimmu.2023.1101446","article-title":"Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques","volume":"14","author":"Pampusch","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.117461_bb0385","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood.2025032093","article-title":"CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial","volume":"148","author":"Nunez","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117461_bb0390","doi-asserted-by":"crossref","first-page":"1329850","DOI":"10.3389\/fimmu.2023.1329850","article-title":"Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine?","volume":"14","author":"Filioglou","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117461_bb0395","doi-asserted-by":"crossref","first-page":"1140541","DOI":"10.3389\/fimmu.2023.1140541","article-title":"Combining chemotherapy with CAR-T cell therapy in treating solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"issue":"Pt 2","key":"10.1016\/j.intimp.2026.117461_bb0400","article-title":"Augmentation of NK-cell activity and immunity by combined natural polyphenols and saccharides in vitro and in vivo","volume":"268","author":"Park","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117461_bb0405","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008975","article-title":"Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma","volume":"12","author":"Bharadwaj","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0410","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-025-01759-2","article-title":"In vivo CAR cell therapy: from bench to bedside","volume":"18","author":"Xu","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2026.117461_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2026.104089","article-title":"The rituximab paradox in rheumatoid arthritis: re-evaluating B-cell depletion depth and the synovial microenvironment","volume":"25","author":"Chen","year":"2026","journal-title":"Autoimmun. Rev."},{"issue":"12","key":"10.1016\/j.intimp.2026.117461_bb0420","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.2215\/CJN.0000000858","article-title":"Lupus nephritis: unmet needs and evolving solutions","volume":"20","author":"Abinti","year":"2025","journal-title":"Clinical journal of the American Society of Nephrology\u202f: CJASN"},{"issue":"6","key":"10.1016\/j.intimp.2026.117461_bb0425","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00276-2024","article-title":"Association of fibrotic-related extracellular vesicle microRNAs with lung involvement in systemic sclerosis","volume":"65","author":"Guiot","year":"2025","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2026.117461_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102598","article-title":"FAPi PET\/CT for assessment and visualisation of active myositis-related interstitial lung disease: a prospective observational pilot study","volume":"72","author":"Kastrati","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0435","first-page":"e17","article-title":"Exploring the Potential Value of [ 68 Ga]Ga-FAPI-46 PET\/CT for Molecular Assessment of Fibroblast Activation in Interstitial Lung Disease\u202f: A Single-Center Pilot Study","volume":"50","author":"Bahtouee","year":"2025","journal-title":"Clin. Nucl. Med."},{"issue":"8","key":"10.1016\/j.intimp.2026.117461_bb0440","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/art.41703","article-title":"Molecular signatures of kidney antibody-secreting cells in lupus patients with active nephritis upon immunosuppressive therapy","volume":"73","author":"Crickx","year":"2021","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"10","key":"10.1016\/j.intimp.2026.117461_bb0445","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1164\/rccm.202503-0535OC","article-title":"One-year change in quantitative computed tomography is associated with meaningful outcomes in fibrotic lung disease","volume":"211","author":"Koslow","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.intimp.2026.117461_bb0450","doi-asserted-by":"crossref","DOI":"10.1002\/art.70236","article-title":"Integrated clinical and proteomic profiling of CD19 chimeric antigen receptor T cell therapy in progressive systemic sclerosis","author":"Jia","year":"2026","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"6","key":"10.1016\/j.intimp.2026.117461_bb0455","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.ymthe.2024.11.035","article-title":"Managing allorejection in off-the-shelf CAR-engineered cell therapies","volume":"33","author":"Li","year":"2025","journal-title":"Molecular therapy\u202f: the journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.intimp.2026.117461_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102596","article-title":"Chimeric antigen receptor T cell therapy for autoimmune diseases","volume":"95","author":"Nie","year":"2025","journal-title":"Curr. Opin. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2026.117461_bb0465","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.tibtech.2024.09.013","article-title":"Rapid manufacturing of CAR-T therapy: strategies and impact","volume":"43","author":"Chen","year":"2025","journal-title":"Trends Biotechnol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117461_bb0470","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005400","article-title":"Generation and proof-of-concept for allogeneic CD123 CAR-Delta one T (DOT) cells in acute myeloid leukemia","volume":"10","author":"Sanchez Martinez","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.intimp.2026.117461_bb0475","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo CAR engineering for immunotherapy","volume":"25","author":"Li","year":"2025","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117461_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2026.102929","article-title":"Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation","volume":"37","author":"Picht","year":"2026","journal-title":"Molecular therapy Nucleic acids"},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0485","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tips.2025.11.001","article-title":"Autologous, allogeneic, in vivo CAR for autoimmune diseases","volume":"47","author":"Li","year":"2026","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2026.117461_bb0490","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/bjd\/ljad089","article-title":"Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers","volume":"189","author":"Carter","year":"2023","journal-title":"Br. J. Dermatol."},{"issue":"8","key":"10.1016\/j.intimp.2026.117461_bb0495","article-title":"Emerging trends in clinical allogeneic CAR cell therapy","volume":"6","author":"Li","year":"2025","journal-title":"Med (New York, NY)"},{"issue":"9","key":"10.1016\/j.intimp.2026.117461_bb0500","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.molmed.2025.01.011","article-title":"Is there a place for engineered immune cell therapies in autoimmune diseases?","volume":"31","author":"Perico","year":"2025","journal-title":"Trends Mol. Med."},{"issue":"6","key":"10.1016\/j.intimp.2026.117461_bb0505","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3324\/haematol.2023.284604","article-title":"Allogeneic chimeric antigen receptor T cells for children with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"109","author":"Locatelli","year":"2024","journal-title":"Haematologica"},{"issue":"34","key":"10.1016\/j.intimp.2026.117461_bb0510","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1038\/s41388-022-02416-5","article-title":"ROR1-targeting switchable CAR-T cells for cancer therapy","volume":"41","author":"Peng","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2026.117461_bb0515","doi-asserted-by":"crossref","first-page":"1613622","DOI":"10.3389\/fimmu.2025.1613622","article-title":"CAR-based cell therapy for autoimmune diseases","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117461_bb0520","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.686439","article-title":"Precision engineering of an anti-HLA-A2 chimeric antigen receptor in regulatory T cells for transplant immune tolerance","volume":"12","author":"Muller","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117461_bb0525","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1684023","article-title":"Loss of TET function in T regulatory cells yields ex-Treg cells biased toward T follicular helper cells, causing autoimmune diseases through autoantibody production","volume":"17","author":"Suzuki","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117461_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107297","article-title":"Fragile Treg cells: traitors in immune homeostasis?","volume":"206","author":"Song","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"12","key":"10.1016\/j.intimp.2026.117461_bb0535","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11926-024-01164-7","article-title":"Recent updates on the pathogenesis of inflammatory myopathies","volume":"26","author":"Musai","year":"2024","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.intimp.2026.117461_bb0580","article-title":"Chimeric antigen receptor T-cell revolution remodeling immunity to conquer autoimmune disease","volume":"9","author":"Shao","year":"2026","journal-title":"Research (Washington, DC)"},{"issue":"7","key":"10.1016\/j.intimp.2026.117461_bb0585","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.3324\/haematol.2023.283874","article-title":"GPIbalpha CAAR T cells function like a trojan horse to eliminate autoreactive B cells to treat immune thrombocytopenia","volume":"109","author":"Zhou","year":"2024","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.intimp.2026.117461_bb0590","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41587-026-03001-x","article-title":"Clinical progress of engineered cellular immunotherapies for autoimmunity","volume":"44","author":"Solimani","year":"2026","journal-title":"Nat. Biotechnol."},{"issue":"11","key":"10.1016\/j.intimp.2026.117461_bb0595","doi-asserted-by":"crossref","DOI":"10.3390\/cells12111534","article-title":"CAR-based therapy for autoimmune diseases: a novel powerful option","volume":"12","author":"Muzes","year":"2023","journal-title":"Cells"},{"issue":"771","key":"10.1016\/j.intimp.2026.117461_bb0600","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ado2084","article-title":"Engineering CAR-T therapies for autoimmune disease and beyond","volume":"16","author":"English","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0540","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12016-025-09114-6","article-title":"Chimeric antigen receptor T cell therapy in systemic lupus erythematosus: mechanisms, clinical advances, and future directions a comprehensive review","volume":"68","author":"Matarneh","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.intimp.2026.117461_bb0605","doi-asserted-by":"crossref","first-page":"1548979","DOI":"10.3389\/fimmu.2025.1548979","article-title":"In-depth analysis of the safety of CAR-T cell therapy for solid tumors","volume":"16","author":"Dong","year":"2025","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117461_bb0610","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tips.2024.07.005","article-title":"Frontiers in CAR-T cell therapy for autoimmune diseases","volume":"45","author":"Li","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2026.117461_bb0615","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"17","key":"10.1016\/j.intimp.2026.117461_bb0620","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1182\/blood.2024025413","article-title":"CAR T cells in autoimmunity: game changer or stepping stone?","volume":"145","author":"Mougiakakos","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0625","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1186\/s12967-025-07183-x","article-title":"Preventing secondary primary malignancies (SPMs) in CAR-T cell therapy through site-specific transgene integration into genomic safe harbors (GSHs)","volume":"23","author":"Safarzadeh Kozani","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0630","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-024-01602-0","article-title":"Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China\u2019s responses to address secondary cancer risks of CAR-T therapy","volume":"17","author":"Tan","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2026.117461_bb0635","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1200\/JCO.22.00478","volume":"41","author":"Vijenthira","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117461_bb0640","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315990121","article-title":"Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy","volume":"121","author":"Qin","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.intimp.2026.117461_bb0645","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2025.11.027","article-title":"CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement","volume":"84","author":"Keitel","year":"2026","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117461_bb0335","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"M\u00fcller","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.117461_bb0340","doi-asserted-by":"crossref","unstructured":"Shan L, Wang Z, Li S, Cui X, Li T, Wang C, Zhao C, Zheng Q, Xu X, Wang S et al: Autologous CD19 CAR-T cell therapy for pediatric and adult systemic lupus erythematosus: a phase 1\/2 trial. Mol. Ther. 2026, 34(7):4054\u20134069.","DOI":"10.1016\/j.ymthe.2026.03.037"},{"issue":"5","key":"10.1016\/j.intimp.2026.117461_bb0345","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ard.2025.12.014","article-title":"Heterogeneous responses of IM19 anti-CD19 CAR T-cell therapy in refractory systemic lupus erythematosus: an open-label pilot study and a mini-review","volume":"85","author":"Zhao","year":"2026","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2026.117461_bb0545","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S2213-2600(24)00267-4","article-title":"Idiopathic inflammatory myopathies related lung disease in adults","volume":"13","author":"Sehgal","year":"2025","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.intimp.2026.117461_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103455","article-title":"Idiopathic inflammatory myopathies - the burden of disease: cohort analysis focusing on damage and comorbidities","volume":"22","author":"Campar","year":"2023","journal-title":"Autoimmun. Rev."},{"issue":"11","key":"10.1016\/j.intimp.2026.117461_bb0555","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41584-023-01032-1","article-title":"Back to the future: targeting the extracellular matrix to treat systemic sclerosis","volume":"19","author":"Leask","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2026.117461_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103621","article-title":"Anti-BCMA\/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial","volume":"90","author":"Zhang","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0565","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.117461_bb0570","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/bjd\/ljaf311","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus","volume":"194","author":"Didona","year":"2026","journal-title":"Br. J. Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117461_bb0575","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jgg.2022.05.005","article-title":"Current status and perspectives of regulatory T cell-based therapy","volume":"49","author":"Qu","year":"2022","journal-title":"Journal of genetics and genomics = Yi chuan xue bao"},{"issue":"5","key":"10.1016\/j.intimp.2026.117461_bb0650","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.kint.2026.01.032","article-title":"Tiny warriors, big impact: targeted immunotherapy in kidney diseases","volume":"109","author":"Kurzhagen","year":"2026","journal-title":"Kidney Int."},{"issue":"10","key":"10.1016\/j.intimp.2026.117461_bb0655","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/CM9.0000000000003111","article-title":"Dawn of CAR-T cell therapy in autoimmune diseases","volume":"137","author":"Liu","year":"2024","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"10.1016\/j.intimp.2026.117461_bb0660","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1182\/blood.2025028960","article-title":"A single-cell atlas of bone marrow B cells reveals defective central B-cell tolerance in immune thrombocytopenia","volume":"147","author":"Sheng","year":"2026","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2026.117461_bb0665","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s44321-024-00043-z","article-title":"B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis","volume":"16","author":"Tian","year":"2024","journal-title":"EMBO Mol. Med."},{"issue":"3","key":"10.1016\/j.intimp.2026.117461_bb0670","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.ymthe.2025.12.022","article-title":"Redefining multiple sclerosis with CAR-T cell therapy","volume":"34","author":"Li","year":"2026","journal-title":"Molecular therapy\u202f: the journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.intimp.2026.117461_bb0675","doi-asserted-by":"crossref","first-page":"1101769","DOI":"10.3389\/fimmu.2023.1101769","article-title":"The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926013081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926013081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:37:26Z","timestamp":1790282246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926013081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":135,"alternative-id":["S1567576926013081"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117461","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-based therapies in systemic autoimmunity: from deep immune depletion toward durable immune reset","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117461","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117461"}}